摘要
目的:观察奥曲肽治疗肝硬化门脉高压症患者时对窦性心律的影响,并对奥曲肽降低门脉压力的作用机制进行探讨.方法:249例住院的肝硬化门脉高压症合并食管胃底静脉曲张破裂出血患者,根据是否应用奥曲肽分成奥曲肽组(n=153)和对照组(n=96).奥曲肽组用奥曲肽0.3~0.7 mg·d-1,其他治疗与对照组相同.对两组患者在治疗前、治疗后24 h,72 h及1周时的血压和心率进行监测.结果:治疗前后两组间的血压及治疗前、治疗后24 h时两组间的心率均无差异,而治疗后72 h及1周时奥曲肽组的心率均明显低于对照组,而且奥曲肽组窦性心动过缓的发生率达6.54%(10/153),高于对照组的1.04%(1/96).结论:奥曲肽可明显降低肝硬化门脉高压症患者的心率,并可引起部分患者严重窦性心动过缓.
Objective:To assess whether octreotide affects the sinus rhythm when it is applied to treat the portal hypertension associated with liver cirrhosis and investigate the mechanism of octreotide in the reduction of the portal hypertension. Methods: Two hundred and forty nine patients with portal hypertension associated with liver cirrhosis and hemorrhage from esophageal and stomach fundic varices were randomly assigned to either octreotide (0.3 - 0.7 mg·day^-1 , n = 153) group or comparative control ( n = 96) group. The blood pressure and heart rate were monitored before the treatment and at 24, 72 hours and one week after the treatment. Results:No statistical differences of blod pressure and heart rate at 24 hours post the treatment were observed in both groups. The octreotide patients experienced significant sinus bradycardia at 72 hours and one week post the treatment, compared with the patients in the comparative group. The incidence of sinus bradycardia in the octreotide and control group was 6.54% versus 1.04%, respectively. Conclusion: Octreotide can significantly slow down the heart rate with sinus bradycardia incidence of treatment-related adverse events in patients with portal hypertension associated with liver cirrhosis.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2005年第8期1051-1054,共4页
Chinese Journal of New Drugs